Switzerland's Cytos Biotechnology AG, which discovers and develops newprotein drugs and protein-based immunotherapeutics, has been awarded US Patent No 6,197,502, Expression cloning process for the discovery, characterization and isolation of genes encoding polypeptides with a predetermined property.
Cytos chief executive Wolfgang Renner says that, with this patent, the company has secured broad protection for an essential technology that facilitates drug discovery and differentiates its system from that of competitors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze